Our results are in line with studies showing that reducing circulating insulin with diazoxide [5], partial ablation of the Ins1 gene [6, 7] or the inhibition of insulin signalling by genetic or pharmacological approaches [30, 31] protects from obesity and the metabolic syndrome. This evidence concerns the gene FOXM1 and obesity disorder.